ロード中...
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx...
保存先:
| 出版年: | Ann Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5035792/ https://ncbi.nlm.nih.gov/pubmed/27502705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw288 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|